Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

62.70 -2.90 (-4.42%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Here are the top movers in Tuesday's session. ↗

September 02, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

10 Health Care Stocks Whale Activity In Today's Session ↗

September 02, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 02, 2025

Via Benzinga

Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results ↗

September 02, 2025

Via Benzinga

Topics Stocks

Retail Buzz Soars As Cytokinetics Jumps 34% In Europe On Heart Drug Breakthrough ↗

September 01, 2025

Via Stocktwits

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session. ↗

September 02, 2025

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Via Chartmill

Cytokinetics (CYTK) Stock Is Skyrocketing Tuesday: What's Driving The Action? ↗

September 02, 2025

Shares of Cytokinetics are trading sharply higher Tuesday. The company presented new long-term safety and efficacy data for its investigational drug, aficamten.

Via Benzinga

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

September 02, 2025

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Tuesday's pre-market session: top gainers and losers ↗

September 02, 2025

As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 02, 2025

Via Benzinga

Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket ↗

September 02, 2025

Via Benzinga

Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease ↗

August 30, 2025

Cytokinetics said Saturday its experimental treatment for a progressive heart disease outperformed standard beta blockers.

Via Investor's Business Daily

Tesla Stock 'Could Fall 90% Tomorrow,' Fund Manager Still Won't Buy — Here's Where He's Investing Instead ↗

August 26, 2025

A fund manager who beats 99% of his peers calls Tesla stock overvalued. Here's a look at some of his preferred investments.

Via Benzinga

CYTK Earnings Jump 3,065% ↗

August 07, 2025

Via The Motley Fool

Topics Economy Intellectual Property

Securities Fraud Investigation Into Cytokinetics, Incorporated (CYTK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

May 08, 2025

From Glancy Prongay & Murray LLP

Via Business Wire

Cytokinetics, Incorporated (CYTK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

May 08, 2025

From Law Offices of Howard G. Smith

Via Business Wire

Securities Fraud Investigation Into Cytokinetics, Incorporated (CYTK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

May 07, 2025

From Law Offices of Frank R. Cruz

Via Business Wire

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm

May 02, 2025

From The Schall Law Firm

Via Business Wire

FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months ↗

May 02, 2025

FDA extended the aficamten decision deadline to Dec. 26 after classifying the REMS submission as a major amendment to the NDA review.

Via Benzinga

Cytokinetics, Incorporated Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CYTK

May 02, 2025

From DJS Law Group

Via Business Wire

Block, Atlassian, Apple, Roku, Amazon And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

May 02, 2025

Via Benzinga

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

May 01, 2025

The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.

Via Chartmill

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 01, 2025

Via Benzinga

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday ↗

April 24, 2025

Via Benzinga

Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach ↗

April 21, 2025

FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use

Via Benzinga

Which stocks are moving after the closing bell on Wednesday? ↗

April 16, 2025

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 16, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.